ANI Pharmaceuticals Inc (ANIP)

Sep 26, 2026

Bank of America Corp DE has acquired 183,066 shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), valued at approximately $15.2 million, giving them a 0.80% stake in the company. Other institutional investors have also increased their holdings, with institutional investors now owning 76.05% of the company's stock. Despite recent insider selling, ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 EPS on $266.04 million in revenue, and has issued fiscal 2026 EPS guidance of $9.19–$9.69.

Sep 23, 2026

Oppenheimer has initiated coverage of ANI Pharmaceuticals (ANIP) with a "Perform" rating and an $85 price target. The company currently has an average analyst rating of "overweight" and a mean price target of $105.78 from other analysts.

Sep 16, 2026

ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the company's stock for $383,400.00 on September 15th, reducing his stake by 1.57%. This transaction occurred under a pre-arranged Rule 10b5-1 plan. The company recently reported strong quarterly earnings, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $105.57.

Sep 15, 2026

Cook Meredith, Senior VP, General Counsel & Secretary at ANI Pharmaceuticals (NASDAQ: ANIP), sold 500 shares of the company stock on September 14, 2026, at a price of $70.79 per share. Following this transaction, Meredith retains 73,924 shares. The sale represented approximately 0.7% of Meredith's previous holdings, providing transparency on the scale of the disposal.

Sep 15, 2026

Squarepoint Ops LLC significantly reduced its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by selling 37,088 shares, now owning 26,450 shares valued at $2.19 million. This comes as ANI Pharmaceuticals exceeded quarterly earnings expectations with $2.21 EPS and a 25.8% revenue increase. Despite insider selling, analysts maintain a "Moderate Buy" consensus with an average price target of $105.57.

Sep 15, 2026

ANI Pharmaceuticals Director Jeanne Thoma sold 1,000 shares of ANIP stock for $71,530 on September 11, 2026, reducing her holdings by 3.6% to 26,762 shares. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company's stock was trading near its 12-month low, despite a recent earnings beat and a "Moderate Buy" consensus rating from analysts with an average price target of $105.57.

Sep 15, 2026

ANI Pharmaceuticals VP Meredith Cook recently sold 500 shares of ANIP stock for $35,395, part of a pre-arranged trading plan, bringing her total direct ownership to 73,924 shares. This follows two similar sales since July, occurring as the stock traded near its 12-month low despite the company reporting strong quarterly earnings and revenue growth. Analyst sentiment remains positive with a "Moderate Buy" consensus, and institutional investors hold a significant portion of the company's stock.

Sep 14, 2026

Amundi significantly increased its stake in ANI Pharmaceuticals by 595.5% in the second quarter, now holding 31,793 shares valued at $2.6 million. This comes as ANI Pharmaceuticals reported strong quarterly earnings, beating analyst expectations with an EPS of $2.21 and revenue up 25.8% year-over-year. Despite mixed analyst ratings, the consensus remains a "Moderate Buy" with an average price target of $105.57.

Sep 13, 2026

Virginia Retirement Systems recently acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), purchasing 17,500 shares valued at approximately $1.45 million. Institutional investors now collectively own 76.05% of the specialty pharmaceutical company. ANI Pharmaceuticals also reported strong quarterly earnings, beating analyst expectations with $2.21 EPS and $266.04 million in revenue, while analysts currently maintain a "Moderate Buy" consensus rating for the stock.